Drugs News and Research

RSS

Ambrisentan cleared for use with phenprocoumon

Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers.

7 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2014.

7 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

First Edition: May 7, 2014

Today's headlines include a story noting that insurers say about 80 percent of new enrollees have paid their first premiums for new insurance coverage under the health law.

7 May 2014

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

The Translational Genomics Research Institute (TGen) and George Mason University today announced the creation of a strategic research alliance to benefit patients with cancer and other life-threatening illnesses.

7 May 2014

Viewpoints: Obamacare a 'Hispanic success story'; another day in court for health law challengers

It makes obvious sense to attribute the surge to the Affordable Care Act, which kicked into full gear in the January-March period measured by the Bureau of Economic Analysis figures.

7 May 2014

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

More than a million people are treated for mild traumatic brain injuries in U.S. hospitals and emergency rooms each year. Yet few receive appropriate psychological and social follow-up care that can make the difference in whether or not they fully recover.

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.

6 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.

6 May 2014

Triple-S Management reports consolidated revenues of $584.8 million for first quarter 2014

Triple-S Management Corporation, the leading managed care company in Puerto Rico, today announced consolidated revenues of $584.8 million and consolidated operating income of $10.0 million for the three months ended March 31, 2014.

6 May 2014

Nanoviricides develops new drug candidates against MERS infection

...

6 May 2014

Concise analysis of global disposable gloves market

MRRBIZ includes new market research report "Disposable Gloves Market For Medical and Non-Medical (Food, Cleanroom, Industrial And Other) Applications - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019" to its large collection of research report.

6 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

The Jeffrey Epstein VI Foundation supports Sunscreen Innovation Act to combat melanoma

Sunscreens are long overdue for a makeover: in fact active ingredients in US sunscreens haven't been updated for fifteen years, despite dermatologist and oncologist warnings that US sunscreens are not effective enough.

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.

6 May 2014

Drugs News and Research

Ambrisentan cleared for use with phenprocoumon

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

First Edition: May 7, 2014

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

Viewpoints: Obamacare a 'Hispanic success story'; another day in court for health law challengers

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Naurex's two lead antidepressant programs achieve major milestones

Triple-S Management reports consolidated revenues of $584.8 million for first quarter 2014

Nanoviricides develops new drug candidates against MERS infection

Concise analysis of global disposable gloves market

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

The Jeffrey Epstein VI Foundation supports Sunscreen Innovation Act to combat melanoma

Debiopharm signs new license and research agreement with Yale University

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News